N-Glycosylation Inhibitor Development Service

N-Glycosylation Inhibitor Development Service

N-Glycosylation Inhibitor Development Service at CD BioGlyco

N-Glycosylation is a key modification process of many important proteins, affecting the stability and activity of proteins, thereby participating in the regulation of biological processes such as cell signaling, immune response, and virus invasion. Develop appropriate N-glycosylation inhibitors as research tools to help deeply understand and elucidate the mechanism of N-glycosylation's impact on cell functions and disease development, and provide important means for research in related fields. As one of the world's most influential biological companies, CD BioGlyco provides various types of N-glycosylation inhibitor development services, including polyol precursor assembly inhibitors, N-glycosylation processing enzyme inhibitors, substrate analog-based N-glycosylation inhibitors and blocking N-glycan-protein interaction inhibitors. Professional N-glycosylation inhibitor development services mainly include the following contents.

  • Inhibitor screening and optimization

CD BioGlyco first identifies the protein or enzyme of interest as a target for the development of N-glycosylation inhibitors. High-throughput screening technology and computational simulation methods are then used to screen candidate compounds with potential N-glycosylation inhibitory activity from the compound library. Based on the structure and active site information of the target protein, N-glycosylation inhibitors with appropriate molecular structures are designed. Subsequently, the activity, selectivity, and sample stability of inhibitors are improved through reasonable chemical modification, molecular simulation, and structure-activity relationship studies.

  • Inhibitor synthesis and analysis

CD BioGlyco provides synthesis and purification for screened N-glycosylation inhibitors. Based on the structure and characteristics of the inhibitors obtained through screening, we determine synthetic pathways and methods, use appropriate reagents, solvents, and conditions for the reaction, and perform necessary purification and crystallization steps to obtain the required N-glycosylation inhibitors. At the same time, we conduct comprehensive analysis and characterization of the synthesized N-glycosylation inhibitors to ensure that their structure and purity meet the requirements. Commonly used analytical techniques include nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), infrared spectroscopy (IR), high-performance liquid chromatography (HPLC), etc.

  • Activity assessment

CD BioGlyco evaluates the activity of optimized N-glycosylation inhibitors and uses in vitro experimental methods to evaluate the inhibitory effect on target proteins or enzymes. For example, determine the inhibition constant, the IC50 value of the inhibitor, and the effect on N-glycosylation modification in a specific cell line.

  • Characteristic evaluation

CD BioGlyco also provides pharmacokinetic (absorption, distribution, metabolism, and excretion/elimination (ADME)) and toxicological evaluation for developed N-glycosylation inhibitors to assess the safety of the candidate inhibitors.

  • Mass production

In addition, we also provide large-scale production for N-glycosylation inhibitors after inhibitors pass preliminary experimental verification, we will optimize the synthesis process route and control the production quality of inhibitors to ensure the production of N-glycosylation inhibitors that meet specifications.

N-Glycosylation inhibitor development services.Fig.1 N-Glycosylation inhibitor development services. (CD BioGlyco)


Technology: Cell extraction or chemical synthesis

Journal: Critical Reviews in Biochemistry and Molecular Biology

IF: 8.697

Published: 2007

Results: The authors described a variety of inhibitors of N-linked glycans, most of which target early steps in the biosynthetic pathway and affect the assembly of all types of N-linked chains. Tunicamycin was a nucleoside analog isolated from Streptomyces streptolyticum and was a polyol precursor assembly inhibitor. Castanospermine inhibited α-glucosidase I and II, and deoxymannojirimycin inhibited ER α-mannosidase I, they were widely used processing enzyme inhibitors. N-Glycosylation inhibitors were very useful for studying the biological functions of N-glycans in cells or tissues.

Various N-glycosylation inhibitors.Fig.2 Various N-glycosylation inhibitors. (Brown, et al., 2007)


  • Drug development: N-Glycosylation is a common protein modification that affects the activity and stability of drugs. The development of N-glycosylation inhibitors is used to optimize the glycosylation pattern of drugs and improve the efficacy and pharmacokinetic properties of drugs.
  • Cancer research: Cancer cells often exhibit abnormal N-glycosylation patterns, leading to tumor growth and metastasis. By developing N-glycosylation inhibitors, we interfere with the glycosylation process of cancer cells and inhibit the growth and spread of tumors.
  • Immune mechanism research: Glycosylation plays an important role in the immune system, affecting the recognition and functions of immune cells. The development of N-glycosylation inhibitors regulates the glycosylation status of immune cells, enhances or inhibits immune responses, and thus conducts research on immune mechanisms.


  • Top inhibitor development technology: CD BioGlyco is equipped with advanced experimental equipment and facilities, using a variety of strategies and technology means to develop and test N-glycosylation inhibitors, including computational simulation, high-throughput screening, etc.
  • Efficient optimization strategy: Our professional technical team improves the selectivity and efficacy of N-glycosylation inhibitors through structural optimization, drug design, and other means.
  • Multi-dimensional evaluation capability: CD BioGlyco conducts a multi-dimensional evaluation of the developed N-glycosylation inhibitors, including evaluation of activity, stability, toxicity, etc.

CD BioGlyco has an experienced team of scientists and technicians who efficiently execute N-glycosylation inhibitor development projects and solve problems that may arise. We are committed to delivering high-quality N-glycosylation inhibitor development results and ensuring that our clients' expectations are met or exceeded. Please feel free to contact us if you are interested in our inhibitor development services.


  1. Brown, J.R.; et al. Glycan antagonists and inhibitors: a fount for drug discovery. Critical Reviews in Biochemistry and Molecular Biology. 2007, 42(6): 481-515.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.